CXCR1 and type 1 diabetes mellitus: Notably, the diversity of mechanisms driving T1D progression across different endotypes and the resulting inter-subject variability may necessitate the development of a panel of disease-modifying therapeutic options for patients, within which CXCR1/2-tarteging therapies may be an important player (32).